A Perspective on Tumor Radiation Resistance Following High-LET Radiation Treatment

Overview

Journal J Cancer Res Clin Oncol

Specialty Oncology

Date 2024 May 2

PMID 38696003

Authors

Yogendra Singh Rajpurohit

Dhirendra Kumar Sharma

Mitu Lal

Ishu Soni

Affiliations

Soon will be listed here.

Abstract

High-linear energy transfer (LET) radiation is a promising alternative to conventional low-LET radiation for therapeutic gain against cancer owing to its ability to induce complex and clustered DNA lesions. However, the development of radiation resistance poses a significant barrier. The potential molecular mechanisms that could confer resistance development are translesion synthesis (TLS), replication gap suppression (RGS) mechanisms, autophagy, epithelial-mesenchymal transition (EMT) activation, release of exosomes, and epigenetic changes. This article will discuss various types of complex clustered DNA damage, their repair mechanisms, mutagenic potential, and the development of radiation resistance strategies. Furthermore, it highlights the importance of careful consideration and patient selection when employing high-LET radiotherapy in clinical settings.

References

Fujisawa H, Nakajima N, Sunada S, Lee Y, Hirakawa H, Yajima H . VE-821, an ATR inhibitor, causes radiosensitization in human tumor cells irradiated with high LET radiation. Radiat Oncol. 2015; 10:175. PMC: 4554350. DOI: 10.1186/s13014-015-0464-y. View

Busato F, El Khouzai B, Mognato M . Biological Mechanisms to Reduce Radioresistance and Increase the Efficacy of Radiotherapy: State of the Art. Int J Mol Sci. 2022; 23(18). PMC: 9499172. DOI: 10.3390/ijms231810211. View

Yang J, Gao J, Hu J, Hu W, Qiu X, Huang Q . Carbon-ion radiotherapy in the treatment of radiation-induced second primary malignancies. Ann Transl Med. 2022; 10(22):1200. PMC: 9761151. DOI: 10.21037/atm-20-200. View

Yock T, Caruso P . Risk of second cancers after photon and proton radiotherapy: a review of the data. Health Phys. 2012; 103(5):577-85. DOI: 10.1097/HP.0b013e3182609ba4. View

Arruebo M, Vilaboa N, Saez-Gutierrez B, Lambea J, Tres A, Valladares M . Assessment of the evolution of cancer treatment therapies. Cancers (Basel). 2013; 3(3):3279-330. PMC: 3759197. DOI: 10.3390/cancers3033279. View

McKenzie G, Harris R, Lee P, ROSENBERG S . The SOS response regulates adaptive mutation. Proc Natl Acad Sci U S A. 2000; 97(12):6646-51. PMC: 18688. DOI: 10.1073/pnas.120161797. View

Tinganelli W, Durante M . Carbon Ion Radiobiology. Cancers (Basel). 2020; 12(10). PMC: 7603235. DOI: 10.3390/cancers12103022. View

Kozmin S, Eot-Houllier G, Reynaud-Angelin A, Gasparutto D, Sage E . Dissecting Highly Mutagenic Processing of Complex Clustered DNA Damage in Yeast . Cells. 2021; 10(9). PMC: 8471780. DOI: 10.3390/cells10092309. View

Keiko Li H, Matsumoto Y, Furusawa Y, Kamada T . PU-H71, a novel Hsp90 inhibitor, as a potential cancer-specific sensitizer to carbon-ion beam therapy. J Radiat Res. 2016; 57(5):572-575. PMC: 5045081. DOI: 10.1093/jrr/rrw054. View

10.

Nusawardhana A, Pale L, Nicolae C, Moldovan G . USP1-dependent nucleolytic expansion of PRIMPOL-generated nascent DNA strand discontinuities during replication stress. Nucleic Acids Res. 2024; 52(5):2340-2354. PMC: 10954467. DOI: 10.1093/nar/gkad1237. View

11.

Adewoye A, Lindsay S, Dubrova Y, Hurles M . The genome-wide effects of ionizing radiation on mutation induction in the mammalian germline. Nat Commun. 2015; 6:6684. PMC: 4389250. DOI: 10.1038/ncomms7684. View

12.

Paganetti H . Mechanisms and Review of Clinical Evidence of Variations in Relative Biological Effectiveness in Proton Therapy. Int J Radiat Oncol Biol Phys. 2021; 112(1):222-236. PMC: 8688199. DOI: 10.1016/j.ijrobp.2021.08.015. View

13.

Barnaba N, LaRocque J . Targeting cell cycle regulation via the G2-M checkpoint for synthetic lethality in melanoma. Cell Cycle. 2021; 20(11):1041-1051. PMC: 8208119. DOI: 10.1080/15384101.2021.1922806. View

14.

Shikazono N, Pearson C, ONeill P, Thacker J . The roles of specific glycosylases in determining the mutagenic consequences of clustered DNA base damage. Nucleic Acids Res. 2006; 34(13):3722-30. PMC: 1557791. DOI: 10.1093/nar/gkl503. View

15.

Liu Y, Zheng C, Huang Y, He M, Xu W, Li B . Molecular mechanisms of chemo- and radiotherapy resistance and the potential implications for cancer treatment. MedComm (2020). 2021; 2(3):315-340. PMC: 8554658. DOI: 10.1002/mco2.55. View

16.

Marini V, Nikulenkov F, Samadder P, Juul S, Knudsen B, Krejci L . MUS81 cleaves TOP1-derived lesions and other DNA-protein cross-links. BMC Biol. 2023; 21(1):110. PMC: 10189953. DOI: 10.1186/s12915-023-01614-1. View

17.

Danforth J, Provencher L, Goodarzi A . Chromatin and the Cellular Response to Particle Radiation-Induced Oxidative and Clustered DNA Damage. Front Cell Dev Biol. 2022; 10:910440. PMC: 9326100. DOI: 10.3389/fcell.2022.910440. View

18.

Shimura T, Kakuda S, Ochiai Y, Kuwahara Y, Takai Y, Fukumoto M . Targeting the AKT/GSK3β/cyclin D1/Cdk4 survival signaling pathway for eradication of tumor radioresistance acquired by fractionated radiotherapy. Int J Radiat Oncol Biol Phys. 2011; 80(2):540-8. DOI: 10.1016/j.ijrobp.2010.12.065. View

19.

Igarashi T, Mazevet M, Yasuhara T, Yano K, Mochizuki A, Nishino M . An ATR-PrimPol pathway confers tolerance to oncogenic KRAS-induced and heterochromatin-associated replication stress. Nat Commun. 2023; 14(1):4991. PMC: 10435487. DOI: 10.1038/s41467-023-40578-2. View

20.

Bright S, Flint D, Martinus D, Turner B, Manandhar M, Ben Kacem M . Targeted Inhibition of DNA-PKcs, ATM, ATR, PARP, and Rad51 Modulate Response to X Rays and Protons. Radiat Res. 2022; 198(4):336-346. PMC: 9648665. DOI: 10.1667/RADE-22-00040.1. View